Pfizer has selected the first drug candidate from a collaboration with Sosei Group to develop drugs for major diseases, which are aimed at targets from the G protein-coupled receptor (GPCR)
Allergan and Sosei’s experimental Alzheimer’s medicine has run into trouble – the companies have called a halt to trials after an unexpected toxicology finding in an animal study.<
